[Clinical trial of UFT against disseminated breast cancer].
A study was carried out in 32 patients with disseminated breast cancer to determine the clinical responses and side-effects of daily administration of 400-600 mg of UFT. According to the Japan Mammary Cancer Society's criteria of response, more than partial response was observed in 11 out of 32 cases (34.4%). Side-effects were observed in 15 cases (46.9%) and these mainly consisted of those involving slight myelosuppression and upper digestive organs, such us nausea and anorexia.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011184:Postoperative Period; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005641:Tegafur; D014498:Uracil